{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:32:14Z","timestamp":1791923534062,"version":"4.3.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["PTC-22-982162"],"award-info":[{"award-number":["PTC-22-982162"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sigrid Rausing Trust Neurogenetics Therapies Programme"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer disease begins in the brain many years before symptoms, but early changes are usually studied after death or indirectly through fluid and imaging biomarkers. Here we show that small brain biopsies collected during ventriculoperitoneal shunt surgery can be used to study Alzheimer disease pathology and protein turnover during life. We analysed biopsies from 18 individuals with suspected normal pressure hydrocephalus, alongside matched ventricular and lumbar cerebrospinal fluid and post-mortem control brain tissue. Amyloid plaques were present in 9 of 18 biopsies, while mature tau tangles were rare. Matrix-assisted laser desorption\/ionization mass spectrometry imaging mapped amyloid plaque chemistry within tissue. Phosphorylated tau 217 was enriched around plaques, supporting a local relationship between amyloid and tau pathology. Stable isotope labelling, which tracks newly made proteins, detected rapid tau labelling within approximately 3\u2009hours and estimated brain tau half-life at about 34 days. Amyloid plaques showed little detectable turnover.<\/jats:p>","DOI":"10.1038\/s41467-026-76494-4","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:50Z","timestamp":1790240570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-6313","authenticated-orcid":false,"given":"Aram","family":"Aslanyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5326-4008","authenticated-orcid":false,"given":"Soumya","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M.","family":"Moncur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-9309","authenticated-orcid":false,"given":"Alicja","family":"Szadziewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-4553","authenticated-orcid":false,"given":"Yingxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-0924","authenticated-orcid":false,"given":"Przemys\u0142aw R.","family":"Kac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-0192","authenticated-orcid":false,"given":"Elena","family":"Camporesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-8727","authenticated-orcid":false,"given":"Chihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-6731","authenticated-orcid":false,"given":"Nupur","family":"Ghoshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4937-2860","authenticated-orcid":false,"given":"Nicolas R.","family":"Barth\u00e9lemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-4020","authenticated-orcid":false,"given":"Jack","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9542-802X","authenticated-orcid":false,"given":"Junyue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7149-017X","authenticated-orcid":false,"given":"Maciej","family":"Dulewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Koutarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Schwetye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-9153","authenticated-orcid":false,"given":"Kaleigh F.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-6442","authenticated-orcid":false,"given":"Francesco","family":"Carletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-9456","authenticated-orcid":false,"given":"Fernando","family":"Gonzalez Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire A.","family":"Leckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-6318","authenticated-orcid":false,"given":"Tatiana A.","family":"Giovannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanza","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6480-9536","authenticated-orcid":false,"given":"Donald L.","family":"Elbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-0378","authenticated-orcid":false,"given":"Lewis","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0678-3774","authenticated-orcid":false,"given":"Laurence","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6660-657X","authenticated-orcid":false,"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hanrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3635","authenticated-orcid":false,"given":"Ross W.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"76494_CR1","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82, 4245\u20134249 (1985).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76494_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A. & Higgins, G. A. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256, 184\u2013185 (1992).","journal-title":"Science"},{"key":"76494_CR3","first-page":"159","volume":"8","author":"M Goedert","year":"1992","unstructured":"Goedert, M., Spillantini, M. G., Cairns, N. J. & Crowther, R. A. Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron Cell Press 8, 159\u2013168 (1992).","journal-title":"Neuron Cell Press"},{"key":"76494_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"76494_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimer\u2019s. Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"76494_CR6","doi-asserted-by":"crossref","unstructured":"Blennow, K. & Zetterberg, H. The past and the future of Alzheimer\u2019s disease fluid biomarkers. J. Alzheimer\u2019s Dis. 62, 1125\u20131140 (2018).","DOI":"10.3233\/JAD-170773"},{"key":"76494_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov, D. S. et al. Plasma biomarkers for Alzheimer\u2019s Disease in relation to neuropathology and cognitive change. Acta Neuropathol. 143, 487\u2013503 (2022). Springer Science and Business Media Deutschland GmbH.","journal-title":"Acta Neuropathol."},{"key":"76494_CR8","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s. Dement. 18, 2669\u20132686 (2022). John Wiley and Sons Inc.","journal-title":"Alzheimer\u2019s. Dement."},{"key":"76494_CR9","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1038\/s41380-021-01434-1","volume":"26","author":"J Licinio","year":"2021","unstructured":"Licinio, J. & Wong, M. L. Molecular Psychiatry special issue: Advances in Alzheimer\u2019s disease. Mol. Psychiatry Springe Nat. 26, 5467\u20135470 (2021).","journal-title":"Mol. Psychiatry Springe Nat."},{"key":"76494_CR10","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1212\/WNL.0000000000007728","volume":"93","author":"VJ Lowe","year":"2019","unstructured":"Lowe, V. J. et al. Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology 93, E29\u2013E39 (2019). Lippincott Williams and Wilkins.","journal-title":"Neurology"},{"key":"76494_CR11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/brain\/aww023","volume":"139","author":"A Schwarz","year":"2016","unstructured":"Schwarz, A. et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139, 1539\u20131550 (2016). Oxford University Press.","journal-title":"Brain"},{"key":"76494_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016). Oxford University Press.","journal-title":"Brain"},{"key":"76494_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110\u2013119 (2016). John Wiley and Sons Inc.","journal-title":"Ann. Neurol."},{"key":"76494_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: A prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"key":"76494_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00401-012-1025-1","volume":"124","author":"I Driscoll","year":"2012","unstructured":"Driscoll, I. et al. Correspondence between in vivo 11C-PiB-PET amyloid imaging and post-mortem, region-matched assessment of plaques. Acta Neuropathol. 124, 823\u2013831 (2012).","journal-title":"Acta Neuropathol."},{"key":"76494_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk, D., Blennow, K., White, L. R. & Launer, L. J. CSF A\u03b2 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652\u2013656 (2003).","journal-title":"Neurology"},{"key":"76494_CR17","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren, N. et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology; 98 (2022).","DOI":"10.1212\/WNL.0000000000200040"},{"key":"76494_CR18","doi-asserted-by":"crossref","unstructured":"Mukherjee, S. et al. Quantification of N-terminal amyloid-\u03b2 isoforms reveals isomers are the most abundant form of the amyloid-\u03b2 peptide in sporadic Alzheimer\u2019s disease. Brain Commun. 3 (2021).","DOI":"10.1093\/braincomms\/fcab028"},{"key":"76494_CR19","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1021\/acschemneuro.1c00474","volume":"12","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee, S. et al. Citrullination of amyloid-\u03b2 peptides in Alzheimer\u2019s disease. ACS Chem. Neurosci. Am. Chem. Soc. 12, 3719\u20133732 (2021).","journal-title":"ACS Chem. Neurosci. Am. Chem. Soc."},{"key":"76494_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021). Lancet Publishing Group.","journal-title":"Lancet Neurol."},{"key":"76494_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. J. Am. Med. Assoc. Am. Med. Assoc. 324, 772\u2013781 (2020).","journal-title":"J. Am. Med. Assoc. Am. Med. Assoc."},{"key":"76494_CR22","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1126\/sciadv.abg4855","volume":"7","author":"W Michno","year":"2021","unstructured":"Michno, W. et al. Following spatial Ab aggregation dynamics in evolving Alzheimer\u2019s disease pathology by imaging stable isotope labeling kinetics. Sci. Adv. [Internet]. 7, 4855\u20134871 https:\/\/www.science.org (2021).","journal-title":"Sci. Adv. [Internet]."},{"key":"76494_CR23","doi-asserted-by":"publisher","first-page":"10706","DOI":"10.1523\/JNEUROSCI.2637-09.2009","volume":"29","author":"P Yan","year":"2009","unstructured":"Yan, P. et al. Characterizing the appearance and growth of amyloid plaques in APP\/PS1 mice. J. Neurosci. 29, 10706\u201310714 (2009).","journal-title":"J. Neurosci."},{"key":"76494_CR24","doi-asserted-by":"crossref","unstructured":"Sheline, Y. I. et al. Effect of escitalopram dose and treatment duration on CSF A\u03b2 levels in healthy older adults. Neurology 95, 2666\u20132674 (2020).","DOI":"10.1212\/WNL.0000000000010725"},{"key":"76494_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43587-022-00310-z","volume":"2","author":"JB Pereira","year":"2022","unstructured":"Pereira, J. B. et al. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer\u2019s disease pathology. Nat. Aging 2, 1138\u20131144 (2022). Springer.","journal-title":"Nat. Aging"},{"key":"76494_CR26","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Review interaction between a\u03b2 and tau in the pathogenesis of alzheimer\u2019s disease. Int J. Biol. Sci. 17, 2181\u20132192 (2021). Ivyspring International Publisher.","journal-title":"Int J. Biol. Sci."},{"key":"76494_CR27","first-page":"505","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom, G. S. Amyloid-\u03b2 and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. Am. Med. Assoc. 71, 505\u2013508 (2014).","journal-title":"JAMA Neurol. Am. Med. Assoc."},{"key":"76494_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat. Neurosci. Nat. Res. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci. Nat. Res."},{"key":"76494_CR29","doi-asserted-by":"publisher","first-page":"23102","DOI":"10.1021\/acsami.1c22734","volume":"14","author":"E van Andel","year":"2022","unstructured":"van Andel, E. et al. Highly specific protein identification by immunoprecipitation-mass spectrometry using antifouling microbeads. ACS Appl Mater. Interfaces Am. Chem. Soc. 14, 23102\u201323116 (2022).","journal-title":"ACS Appl Mater. Interfaces Am. Chem. Soc."},{"key":"76494_CR30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/nm1438","volume":"12","author":"RJ Bateman","year":"2006","unstructured":"Bateman, R. J. et al. protein production and clearance rates in humans using in vivo stable isotope labeling, immunoprecipitation, and tandem mass spectrometry. Nat. Med. 12, 856\u2013861 (2006).","journal-title":"Nat. Med."},{"key":"76494_CR31","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298.e7 (2018). Cell Press.","journal-title":"Neuron"},{"key":"76494_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41582-019-0222-0","volume":"15","author":"RW Paterson","year":"2019","unstructured":"Paterson, R. W. et al. SILK studies\u2014capturing the turnover of proteins linked to neurodegenerative diseases. Nat. Rev. Neurol. 15, 419\u2013427 (2019). Nature Publishing Group.","journal-title":"Nat. Rev. Neurol."},{"key":"76494_CR33","doi-asserted-by":"crossref","unstructured":"Hanrieder, J. et al. L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass Spectrometry. Mol. Cellular Proteomics 10 (2011).","DOI":"10.1074\/mcp.M111.009308"},{"key":"76494_CR34","doi-asserted-by":"crossref","unstructured":"Wildburger. N. C. et al. Amyloid-\u03b2 Plaques in clinical Alzheimer\u2019s disease brain incorporate stable isotope tracer in vivo and exhibit nanoscale heterogeneity. Front Neurol. 9, (2018).","DOI":"10.3389\/fneur.2018.00169"},{"key":"76494_CR35","first-page":"319","volume":"13","author":"M Ikegawa","year":"2023","unstructured":"Ikegawa, M. et al. Mass spectrometry imaging in Alzheimer\u2019s disease. Brain Connect. Mary Ann Liebert Inc 13, 319\u2013333 (2023).","journal-title":"Brain Connect. Mary Ann Liebert Inc"},{"key":"76494_CR36","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. Nat. Res. 26, 398\u2013407 (2020).","journal-title":"Nat. Med. Nat. Res."},{"key":"76494_CR37","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1074\/jbc.RA118.006604","volume":"294","author":"W Michno","year":"2019","unstructured":"Michno, W. et al. Pyroglutamation of amyloid-\u03b2x-42 (A\u03b2x-42) followed by A\u03b21-40 deposition underlies plaque polymorphism in progressing Alzheimer\u2019s disease pathology. J. Biol. Chem. [Internet] 294, 6719\u20136732 (2019). http:\/\/www.jbc.org\/article\/S0021925820366102\/fulltext American Society for Biochemistry and Molecular Biology Inc[cited 2024 Jan 15]Available from.","journal-title":"J. Biol. Chem. [Internet]"},{"key":"76494_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/abbi.1993.1112","volume":"301","author":"DL Miller","year":"1993","unstructured":"Miller, D. L. et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer\u2032s disease. Arch. Biochem Biophys. 301, 41\u201352 (1993). Academic Press.","journal-title":"Arch. Biochem Biophys."},{"key":"76494_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/bbrc.1997.7083","volume":"237","author":"YM Kuo","year":"1997","unstructured":"Kuo, Y. M., Emmerling, M. R., Woods, A. S., Cotter, R. J. & Roher, A. E. Isolation, chemical characterization, and quantitation of A\u03b2 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys. Res Commun. 237, 188\u2013191 (1997). Academic Press.","journal-title":"Biochem Biophys. Res Commun."},{"key":"76494_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.neuron.2011.07.001","volume":"71","author":"MP Kummer","year":"2011","unstructured":"Kummer, M. P. et al. Nitration of tyrosine 10 critically enhances amyloid \u03b2 aggregation and plaque formation. Neuron [Internet] 71, 833\u2013844 (2011). https:\/\/pubmed.ncbi.nlm.nih.gov\/21903077\/ Neuron[cited 2024 Jan 15]Available from.","journal-title":"Neuron [Internet]"},{"key":"76494_CR41","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/brain\/awz066","volume":"142","author":"G Brinkmalm","year":"2019","unstructured":"Brinkmalm, G. et al. Identification of neurotoxic cross-linked amyloid-\u03b2 dimers in the Alzheimer\u2019s brain. Brain [Internet] 142, 1441\u20131457 (2019). Oxford Academic[cited 2025 Jun 11]Available from.","journal-title":"Brain [Internet]"},{"key":"76494_CR42","first-page":"1","volume":"2","author":"YK Al-Hilaly","year":"2014","unstructured":"Al-Hilaly, Y. K. et al. A central role for dityrosine crosslinking of Amyloid-\u03b2 in Alzheimer\u2019s disease. Acta Neuropathol. Commun. [Internet] 2, 1\u201317 (2014). https:\/\/link.springer.com\/articles\/10.1186\/2051-5960-1-83 BioMed Central Ltd[cited 2025 Jun 13]Available from.","journal-title":"Acta Neuropathol. Commun. [Internet]"},{"key":"76494_CR43","doi-asserted-by":"crossref","unstructured":"Mandler, M. et al. Pyroglutamylated amyloid-\u03b2 is associated with hyperphosphorylated tau and severity of Alzheimer\u2019s disease. Acta Neuropathol. Springer Verlag 128:67\u201379 (2014).","DOI":"10.1007\/s00401-014-1296-9"},{"key":"76494_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-025-02914-2","volume":"150","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee, S. et al. Isomerized A\u03b2 in the brain can distinguish the status of amyloidosis in the Alzheimer\u2019s disease spectrum. Acta Neuropathol. 150, 1\u201320 (2025). https:\/\/link.springer.com\/article\/10.1007\/s00401-025-02914-2 150:1 [Internet]. Springer; 2025 [cited 2025 Jul 21]Available from.","journal-title":"Acta Neuropathol."},{"key":"76494_CR45","doi-asserted-by":"crossref","unstructured":"Horie, K. et al. Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. Acta Neuropathol Commun. 8 (2020).","DOI":"10.1186\/s40478-020-01019-z"},{"key":"76494_CR46","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1021\/cb4000376","volume":"8","author":"S Nystr\u00f6m","year":"2013","unstructured":"Nystr\u00f6m, S. et al. Evidence for age-dependent in vivo conformational rearrangement within A\u03b2 amyloid deposits. ACS Chem. Biol. 8, 1128\u20131133 (2013).","journal-title":"ACS Chem. Biol."},{"key":"76494_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70335","volume":"169","author":"S Koutarapu","year":"2025","unstructured":"Koutarapu, S. et al. Post-translational modifications distinguish amyloid-\u03b2 isoforms in cerebral amyloid angiopathy and Alzheimer\u2019s disease. J. Neurochem [Internet] 169, e70335 (2025). John Wiley & Sons, Ltd[cited 2025 Dec 28].","journal-title":"J. Neurochem [Internet]"},{"key":"76494_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1021\/cb700116u","volume":"2","author":"KPR Nilsson","year":"2007","unstructured":"Nilsson, K. P. R. et al. Imaging distinct conformational states of amyloid-\u03b2 fibrils in Alzheimer\u2019s disease using novel luminescent probes. ACS Chem. Biol. 2, 553\u2013560 (2007).","journal-title":"ACS Chem. Biol."},{"key":"76494_CR49","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/jacsau.2c00492","volume":"3","author":"PM Wehrli","year":"2023","unstructured":"Wehrli, P. M. et al. Correlative chemical imaging and spatial chemometrics delineate Alzheimer plaque heterogeneity at high spatial resolution. JACS Au. Am. Chem. Soc. 3, 762\u2013774 (2023).","journal-title":"JACS Au. Am. Chem. Soc."},{"key":"76494_CR50","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jnc.15694","volume":"163","author":"W Michno","year":"2022","unstructured":"Michno, W. et al. Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer\u02bcs dementias. J. Neurochem 163, 233\u2013246 (2022). John Wiley and Sons Inc.","journal-title":"J. Neurochem"},{"key":"76494_CR51","doi-asserted-by":"crossref","unstructured":"Caballero, B. et al. Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nat Commun.12 (2021).","DOI":"10.1038\/s41467-021-22501-9"},{"key":"76494_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","volume":"105","author":"MJ Lee","year":"2013","unstructured":"Lee, M. J., Lee, J. H. & Rubinsztein, D. C. Tau degradation: The ubiquitin\u2013proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 105, 49\u201359 (2013).","journal-title":"Prog. Neurobiol."},{"key":"76494_CR53","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1177\/0271678X18760974","volume":"39","author":"PK Eide","year":"2019","unstructured":"Eide, P. K. & Ringstad, G. Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: A glymphatic magnetic resonance imaging study. J. Cereb. Blood Flow. Metab. 39, 1355\u20131368 (2019). SAGE Publications Ltd.","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"76494_CR54","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway, J. M. et al. Clearance systems in the brain\u2014implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457\u2013470 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"76494_CR55","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jnc.14559","volume":"151","author":"W Michno","year":"2019","unstructured":"Michno, W., Wehrli, P. M., Blennow, K., Zetterberg, H. & Hanrieder, J. Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. J. Neurochem 151, 488\u2013506 (2019). Blackwell Publishing Ltd.","journal-title":"J. Neurochem"},{"key":"76494_CR56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0304-3940(96)12970-0","volume":"215","author":"TC Saido","year":"1996","unstructured":"Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T. & Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173\u2013176 (1996).","journal-title":"Neurosci. Lett."},{"key":"76494_CR57","doi-asserted-by":"publisher","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","volume":"267","author":"H Mori","year":"1992","unstructured":"Mori, H., Takio, K., Ogawara, M. & Selkoe, D. J. Mass spectrometry of purified amyloid B protein in Alzheimer\u2019s disease. J. Biol. Chem. 267, 17082\u201317086 (1992).","journal-title":"J. Biol. Chem."},{"key":"76494_CR58","doi-asserted-by":"crossref","unstructured":"Alawode, D.O.T., Heslegrave, A.J., Fox, N.C., Zetterberg, H. Donanemab removes Alzheimer\u2019s plaques: What is special about its target? The Lancet Healthy Longevity. Elsevier Ltd; 2021.","DOI":"10.1016\/S2666-7568(21)00144-6"},{"key":"76494_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023). American Medical Association.","journal-title":"JAMA"},{"key":"76494_CR60","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos, R. B. et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76, 908\u2013920 (2012).","journal-title":"Neuron"},{"key":"76494_CR61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne, V. L. et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study. Lancet Neurol. 12, 357\u2013367 (2013).","journal-title":"Lancet Neurol."},{"key":"76494_CR62","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"76494_CR63","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"76494_CR64","first-page":"1774","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega, K. G. et al. Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease. Science (1979) 330, 1774 (2010).","journal-title":"Science (1979)"},{"key":"76494_CR65","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.clinbiochem.2006.07.009","volume":"39","author":"CR McCudden","year":"2006","unstructured":"McCudden, C. R. & Kraus, V. B. Biochemistry of amino acid racemization and clinical application to musculoskeletal disease. Clin. Biochem. 39, 1112\u20131130 (2006).","journal-title":"Clin. Biochem."},{"key":"76494_CR66","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1016\/S0021-9258(18)53661-9","volume":"268","author":"AE Roher","year":"1993","unstructured":"Roher, A. E. et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer\u2019s disease. J. Biol. Chem. 268, 3072\u20133083 (1993).","journal-title":"J. Biol. Chem."},{"key":"76494_CR67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0021-9258(19)75855-4","volume":"262","author":"T Geiger","year":"1987","unstructured":"Geiger, T. & Clarke, S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J. Biol. Chem. 262, 785\u2013794 (1987). Elsevier.","journal-title":"J. Biol. Chem."},{"key":"76494_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/alzrt254","volume":"6","author":"ME Murray","year":"2014","unstructured":"Murray, M. E. & Dickson, D. W. Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer\u2019s disease? Alzheimer\u2019s. Res. Ther. 6, 24 (2014). https:\/\/link.springer.com\/article\/10.1186\/alzrt2543 [Internet]. BioMed Central; 2014 [cited 2026 Jan 11]; 6Available from.","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"76494_CR69","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","volume":"3","author":"CA Lemere","year":"1996","unstructured":"Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid \u03b2-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16\u201332 (1996).","journal-title":"Neurobiol. Dis."},{"key":"76494_CR70","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awt362","volume":"137","author":"Rijal Upadhaya","year":"2014","unstructured":"Rijal Upadhaya et al. Biochemical stages of amyloid-\u03b2 peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer\u2019s disease. Brain 137, 887\u2013903 (2014).","journal-title":"Brain"},{"key":"76494_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63328-y","volume":"16","author":"JI Wood","year":"2025","unstructured":"Wood, J. I. et al. Isotope-encoded spatial biology identifies plaque-age-dependent maturation and synaptic loss in an Alzheimer\u2019s disease mouse model. Nat. Commun. 16, 8170 (2025). https:\/\/www.nature.com\/articles\/s41467-025-63328-y 16:1 [Internet]. Nature Publishing Group; 2025 [cited 2025 Dec 2]Available from.","journal-title":"Nat. Commun."},{"key":"76494_CR72","doi-asserted-by":"crossref","unstructured":"Giovannini, J. et al. Tau protein aggregation: Key features to improve drug discovery screening. Drug Discovery Today. 27 (2022).","DOI":"10.1016\/j.drudis.2022.01.009"},{"key":"76494_CR73","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.neuron.2019.12.015","volume":"105","author":"B Bai","year":"2020","unstructured":"Bai, B. et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer\u2019s disease progression. Neuron 105, 975\u2013991.e7 (2020).","journal-title":"Neuron"},{"key":"76494_CR74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10561-008-9067-2","volume":"9","author":"TG Beach","year":"2008","unstructured":"Beach, T. G. et al. The sun health research institute brain donation program: Description and experience, 1987\u20132007. Cell Tissue Bank 9, 229\u2013245 (2008).","journal-title":"Cell Tissue Bank"},{"key":"76494_CR75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/nen.0b013e31802c3e7d","volume":"66","author":"I Ferrer","year":"2007","unstructured":"Ferrer, I. et al. Brain protein preservation largely depends on the postmortem storage temperature: Implications for study of proteins in human neurologic diseases and management of brain banks: A BrainNet Europe study. J. Neuropathol. Exp. Neurol. [Internet] 66, 35\u201346 (2007). https:\/\/academic.oup.com\/jnen\/article\/66\/1\/35\/2916704 Available from.","journal-title":"J. Neuropathol. Exp. Neurol. [Internet]"},{"key":"76494_CR76","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0197-4580(98)00094-3","volume":"19","author":"U Gartner","year":"1998","unstructured":"Gartner, U., Janke, C., Holzer, M., Vanmechelen, E. & Arendt, T. Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol. Aging 19, 535\u2013543 (1998).","journal-title":"Neurobiol. Aging"},{"key":"76494_CR77","first-page":"1914","volume":"282","author":"M Hong","year":"1998","unstructured":"Hong, M. et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1979) 282, 1914\u20131917 (1998).","journal-title":"Science (1979)"},{"key":"76494_CR78","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.1471-4159.2005.03641.x","volume":"96","author":"SD Ginsberg","year":"2006","unstructured":"Ginsberg, S. D., Che, S., Counts, S. E. & Mufson, E. J. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer\u2019s disease. J. Neurochem 96, 1401\u20131408 (2006).","journal-title":"J. Neurochem"},{"key":"76494_CR79","doi-asserted-by":"crossref","unstructured":"Horie, K., Barthelemy, N.R., Sato, C., Bateman, R.J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain. Oxford University Press 515\u2013527 (2021).","DOI":"10.1093\/brain\/awaa373"},{"key":"76494_CR80","doi-asserted-by":"crossref","unstructured":"Rostgaard, N. et al. Differential proteomic profile of lumbar and ventricular cerebrospinal fluid. Fluids Barriers CNS. 20 (2023).","DOI":"10.1186\/s12987-022-00405-0"},{"key":"76494_CR81","doi-asserted-by":"crossref","unstructured":"Pyykk\u00f6, O. T. et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PLoS One. 9 (2014).","DOI":"10.1371\/journal.pone.0091974"},{"key":"76494_CR82","doi-asserted-by":"crossref","unstructured":"Greenberg, A.B.W. et al. Utility of cortical tissue analysis in normal pressure hydrocephalus. Cerebral Cortex [Internet]. Available from: https:\/\/academic.oup.com\/cercor\/advance-article\/doi\/10.1093\/cercor\/bhae001\/7588555 (2024).","DOI":"10.1093\/cercor\/bhae001"},{"key":"76494_CR83","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ana.22100","volume":"68","author":"V Leinonen","year":"2010","unstructured":"Leinonen, V. et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer\u2019s disease. Ann. Neurol. 68, 446\u2013453 (2010). John Wiley and Sons Inc.","journal-title":"Ann. Neurol."},{"key":"76494_CR84","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/acn3.657","volume":"5","author":"WK Self","year":"2018","unstructured":"Self, W. K. et al. Protein production is an early biomarker for RNA-targeted therapies. Ann. Clin. Transl. Neurol. 5, 1492\u20131504 (2018). Wiley-Blackwell.","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"76494_CR85","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1373\/jalm.2019.030080","volume":"5","author":"MM Budelier","year":"2020","unstructured":"Budelier, M. M. & Bateman, R. J. Biomarkers of Alzheimer disease. J. Appl. Lab. Med. 5, 194\u2013208 (2020). Oxford University Press.","journal-title":"J. Appl. Lab. Med."},{"key":"76494_CR86","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41380-019-0396-2","volume":"24","author":"MG Sharoar","year":"2019","unstructured":"Sharoar, M. G., Hu, X., Ma, X. M., Zhu, X. & Yan, R. Sequential formation of different layers of dystrophic neurites in Alzheimer\u2019s brains. Mol. Psychiatry 24, 1369\u20131382 (2019). Nature Publishing Group.","journal-title":"Mol. Psychiatry"},{"key":"76494_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/exnr.1996.0133","volume":"141","author":"JC Vickers","year":"1996","unstructured":"Vickers, J. C. et al. Dystrophic neurite formation associated with age-related beta amyloid deposition in the neocortex: Clues to the genesis of neurofibrillary pathology. Exp. Neurol. 141, 1\u201311 (1996). Academic Press.","journal-title":"Exp. Neurol."},{"key":"76494_CR88","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/exnr.1998.7010","volume":"156","author":"TC Dickson","year":"1999","unstructured":"Dickson, T. C., King, C. E., McCormack, G. H. & Vickers, J. C. Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer\u2019s disease. Exp. Neurol. 156, 100\u2013110 (1999). Academic Press.","journal-title":"Exp. Neurol."},{"key":"76494_CR89","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1046\/j.1471-4159.2001.00346.x","volume":"77","author":"N Ghoshal","year":"2001","unstructured":"Ghoshal, N. et al. Tau-66: Evidence for a novel tau conformation in alzheimer\u2019s disease. J. Neurochem 77, 1372\u20131385 (2001).","journal-title":"J. Neurochem"},{"key":"76494_CR90","doi-asserted-by":"crossref","unstructured":"Hirota, Y. et al. Distinct brain pathologies associated with Alzheimer\u2019s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-\u03b2 amyloidosis. Brain Commun. 4 (2022).","DOI":"10.1093\/braincomms\/fcac286"},{"key":"76494_CR91","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. Nat. Res. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med. Nat. Res."},{"key":"76494_CR92","unstructured":"Eisai Global. Eisai Presents Latest Analysis of Lecanemab\u2019s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer\u2019s Association International Conference (AAIC) 2023. (2023)."},{"key":"76494_CR93","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. [Internet] 384, 1691\u20131704 http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2100708 (2021).","journal-title":"N. Engl. J. Med. [Internet]"},{"key":"76494_CR94","doi-asserted-by":"crossref","unstructured":"Alonso, A. D., Beharry, C., Corbo, C. P. & Cohen, L. S. Molecular mechanism of prion-like tau-induced neurodegeneration. Alzheimer\u2019s and Dementia. 12, 1090\u20131097 (2016).","DOI":"10.1016\/j.jalz.2015.12.014"},{"key":"76494_CR95","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1017\/S1355617722000868","volume":"29","author":"D Gold","year":"2022","unstructured":"Gold, D. et al. Longitudinal post-shunt outcomes in idiopathic normal pressure hydrocephalus with and without comorbid Alzheimer\u2019s disease. J. Int. Neuropsychol. Soc. 29, 751\u2013762 (2022). Cambridge University Press.","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"76494_CR96","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jns.2016.08.040","volume":"369","author":"H Kazui","year":"2016","unstructured":"Kazui, H. et al. Association between high biomarker probability of Alzheimer\u2019s disease and improvement of clinical outcomes after shunt surgery in patients with idiopathic normal pressure hydrocephalus. J. Neurol. Sci. 369, 236\u2013241 (2016). Elsevier B.V.","journal-title":"J. Neurol. Sci."},{"key":"76494_CR97","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2018.01.017","volume":"387","author":"YJ Hong","year":"2018","unstructured":"Hong, Y. J. et al. Preoperative biomarkers in patients with idiopathic normal pressure hydrocephalus showing a favorable shunt surgery outcome. J. Neurol. Sci. 387, 21\u201326 (2018). Elsevier B.V.","journal-title":"J. Neurol. Sci."},{"key":"76494_CR98","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1177\/0271678X19874790","volume":"40","author":"PK Eide","year":"2020","unstructured":"Eide, P. K., Valnes, L. M., Pripp, A. H., Mardal, K. A. & Ringstad, G. Delayed clearance of cerebrospinal fluid tracer from choroid plexus in idiopathic normal pressure hydrocephalus. J. Cereb. Blood Flow. Metab. 40, 1849\u20131858 (2020). SAGE Publications Ltd.","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"76494_CR99","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00401-007-0311-9","volume":"115","author":"JPG Vonsattel","year":"2008","unstructured":"Vonsattel, J. P. G., Amaya, M. P. D. & Keller, C. E. Twenty-first century brain banking. Processing brains for research: The Columbia University methods. Acta Neuropathol. 115, 509\u2013532 (2008).","journal-title":"Acta Neuropathol."},{"key":"76494_CR100","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","volume":"28","author":"K Horie","year":"2022","unstructured":"Horie, K. et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat. Med. Nat. Res. 28, 2547\u20132554 (2022).","journal-title":"Nat. Med. Nat. Res."},{"key":"76494_CR101","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1136\/jnnp-2014-310090","volume":"86","author":"L Harper","year":"2015","unstructured":"Harper, L., Barkhof, F., Fox, N. C. & Schott, J. M. Using visual rating to diagnose dementia: A critical evaluation of MRI atrophy scales. J. Neurol. Neurosurg. Psychiatry 86, 1225\u20131233 (2015). BMJ Publishing Group.","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"76494_CR102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13244-016-0521-6","volume":"8","author":"LO Wahlund","year":"2017","unstructured":"Wahlund, L. O. et al. Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Imaging 8, 79\u201390 (2017). Springer Verlag.","journal-title":"Insights Imaging"},{"key":"76494_CR103","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens, P. et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 55, 967\u2013972 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"76494_CR104","first-page":"268","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier, F. et al. Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. Eur. Neurol. 36, 268\u2013272 (1996).","journal-title":"Eur. Neurol."},{"key":"76494_CR105","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I. & Zimmerman, R. A. MR Signal Abnormalities at 1.5\u2009T in Alzheimer\u2019s Dementia and Normal Aging. AJR Am. J. Roentgenol. [Internet] 149, 351\u2013356 www.ajronline.org (1987).","journal-title":"AJR Am. J. Roentgenol. [Internet]"},{"key":"76494_CR106","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/ene.13555","volume":"25","author":"K Kockum","year":"2018","unstructured":"Kockum, K. et al. The idiopathic normal-pressure hydrocephalus Radscale: a radiological scale for structured evaluation. Eur. J. Neurol. 25, 569\u2013576 (2018). Blackwell Publishing Ltd.","journal-title":"Eur. J. Neurol."},{"key":"76494_CR107","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"N Ashton","year":"2024","unstructured":"Ashton, N. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 81, 255 (2024).","journal-title":"JAMA Neurol."},{"key":"76494_CR108","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1007\/s00216-022-04055-x","volume":"414","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee, S., Fjeldsted, J. C., Masters, C. L. & Roberts, B. R. Enhanced ion mobility resolution of Abeta isomers from human brain using high-resolution demultiplexing software. Anal. Bioanal. Chem.\u00a0414, 5683\u20135693 (2022).","journal-title":"Anal. Bioanal. Chem."},{"key":"76494_CR109","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.15487","volume":"159","author":"E Gkanatsiou","year":"2021","unstructured":"Gkanatsiou, E. et al. Amyloid pathology and synaptic loss in pathological aging. J. Neurochem 159, 258\u2013272 (2021). John Wiley and Sons Inc.","journal-title":"J. Neurochem"},{"key":"76494_CR110","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1021\/pr0703627","volume":"6","author":"E Portelius","year":"2007","unstructured":"Portelius, E. et al. Characterization of amyloid \u03b2 peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res 6, 4433\u20134439 (2007).","journal-title":"J. Proteome Res"},{"key":"76494_CR111","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neulet.2019.02.033","volume":"701","author":"E Gkanatsiou","year":"2019","unstructured":"Gkanatsiou, E. et al. A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer\u2019s disease. Neurosci. Lett. Elsevier 701, 125\u2013131 (2019).","journal-title":"Neurosci. Lett. Elsevier"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76494-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:03:01Z","timestamp":1790240581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76494-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76494"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76494-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.G. has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly\/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease) trial. She receives research support from Tau Consortium and Association for Frontotemporal Dementia and is funded by the NIH. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programmes for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Programme, outside the work presented in this paper. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Programme (outside submitted work). LW has received honoraria from and served on advisory boards for Medtronic, B.Braun and Codman. NCF reports consulting fees from Biogen, Eisai, Ionis, Lilly, Roche\/Genentech, and Siemens\u2014all paid to UCL; he has served on a Data Safety Monitoring Board for Biogen. RJB has received research funding from Avid Radiopharmaceuticals, Janssen, Roche\/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive income based on technology (stable isotope labelling kinetics, blood plasma assay, methods of diagnosing AD with phosphorylation changes, neurofilament light chain assays and materials) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. RJB serves as an unpaid member on scientific advisory boards for Roche and Biogen. RWP has received honoraria from GE Healthcare for academic talks and co-leads the Neurofilament light consortium which receives funding from Abbvie, Biogen, Bristol Myers Squibb and Roche. He has equity shares in Guilford Street Laboratories Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9878"}}